DeuteRx Company Profile

Background

Overview:
DeuteRx, established in 2012, is a virtual biopharmaceutical company headquartered in Andover, Massachusetts. The company specializes in enhancing racemic drugs through its proprietary Deuterium-Enabled Chiral Switching (DECS) technology. This innovative approach aims to isolate and stabilize single stereoisomers from racemic mixtures, thereby improving drug efficacy and reducing adverse side effects.

Mission and Vision:
DeuteRx is committed to advancing patient care by transforming existing racemic drugs into more effective and safer therapies. By leveraging its DECS platform, the company seeks to address unmet medical needs across various therapeutic areas.

Key Strategic Focus

Core Objectives:
DeuteRx's primary objective is to apply its DECS technology to develop novel, patent-protected single-enantiomer drugs derived from existing racemic compounds. This strategy aims to enhance therapeutic outcomes and minimize side effects associated with racemic mixtures.

Areas of Specialization:
The company focuses on a broad spectrum of therapeutic indications, including metabolic disorders, oncology, and rare diseases.

Key Technologies Utilized:
Central to DeuteRx's innovation is the DECS platform, which employs deuterium to stabilize preferred stereoisomers, preventing in vivo interconversion and enabling the development of single-enantiomer drugs with improved profiles.

Primary Markets Targeted:
DeuteRx targets markets with significant unmet medical needs, particularly in metabolic diseases like nonalcoholic steatohepatitis (NASH), various forms of cancer, and other specialty or rare conditions.

Financials and Funding

Funding History:
As of September 30, 2015, DeuteRx secured $2.8 million in seed funding. The company has also engaged in strategic transactions, including the sale of certain assets to Poxel SA and Salarius Pharmaceuticals, which have provided additional financial resources to support its operations and research initiatives.

Pipeline Development

Key Pipeline Candidates:

DRX-065 (Deuterium-Stabilized R-Pioglitazone):

Developed for the treatment of NASH, DRX-065 is a mitochondrial pyruvate carrier (MPC) inhibitor. Preclinical and Phase 1 studies suggest it offers enhanced efficacy with reduced side effects compared to traditional pioglitazone. In 2018, Poxel SA acquired DRX-065, intending to advance it into proof-of-concept studies for NASH.

DRX-164 (Deuterium-Stabilized S-Avadomide):

Targeted for hematologic malignancies and solid tumors, DRX-164 is a next-generation, deuterium-stabilized (S)-enantiomer of avadomide. Preclinical models indicate that DRX-164 exhibits anti-tumorigenic activity, potentially offering a better therapeutic profile than avadomide. In January 2022, Salarius Pharmaceuticals acquired DRX-164, rebranded as SP-3164, to further its development in oncology.

Technological Platform and Innovation

Proprietary Technologies:

Deuterium-Enabled Chiral Switching (DECS):

This proprietary platform allows for the stabilization of single stereoisomers in racemic drugs by substituting hydrogen atoms with deuterium at chiral centers. This stabilization prevents in vivo interconversion, leading to drugs with improved efficacy and safety profiles.

Significant Scientific Methods:

Stereoisomer Stabilization:

By employing deuterium substitution, DECS effectively stabilizes the desired stereoisomer, facilitating the development of single-enantiomer drugs from racemic mixtures.

Leadership Team

Key Executives:

Sheila DeWitt, Ph.D.

President, CEO, and Chairman
Dr. DeWitt brings extensive experience in pharmaceutical development and has been instrumental in pioneering the DECS technology at DeuteRx.

Kimberlee Drapkin

Financial Advisor
Ms. Drapkin provides strategic financial guidance, leveraging her background in financial management within the biotech sector.

Vincent Jacques

Vice President of Research & Early Development
Mr. Jacques oversees the company's research initiatives, focusing on the application of DECS across various therapeutic areas.

Board Members:

Leonardus Van der Ploeg, Ph.D.

Board Member and Strategy and R&D Advisor
Dr. Van der Ploeg offers strategic insights into research and development, contributing to the company's scientific direction.

Michael Webb

Board Member and Business Advisor
Mr. Webb provides business strategy expertise, supporting DeuteRx's growth and partnership endeavors.

Leadership Changes

In January 2022, DeuteRx entered into a strategic agreement with Salarius Pharmaceuticals, resulting in the acquisition of DRX-164. As part of this collaboration, certain key employees from DeuteRx are expected to work closely with Salarius to advance the development of SP-3164 and other programs.

Competitor Profile

Market Insights and Dynamics:

The deuterated drugs market was valued at approximately $0.6 billion in 2022 and is projected to reach $1.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.1%. This growth is driven by the increasing recognition of deuterium's potential to enhance drug properties, leading to improved therapeutic outcomes.

Competitor Analysis:

Key players in the deuterated drugs market include: